For instance, although it was initially reported that PF-543 (a potent SPHK1 selective inhibitor) significantly decreased endogenous S1P levels by 10-fold in MD-1483 head and neck carcinoma cells, the data showed no effects on proliferation or survival [207]. This evidence concerns the gene SPHK1 and head and neck carcinoma.